200 related articles for article (PubMed ID: 19126664)
21. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin-II behaves as an endogenous pro-inflammatory molecule.
Das UN
J Assoc Physicians India; 2005 May; 53():472-6. PubMed ID: 16124358
[TBL] [Abstract][Full Text] [Related]
23. Atherosclerosis in the evolution of Alzheimer's disease: can treatment reduce cognitive decline?
Luzzi S; Vella L; Bartolini M; Provinciali L; Silvestrini M
J Alzheimers Dis; 2010; 20(3):893-901. PubMed ID: 20182031
[TBL] [Abstract][Full Text] [Related]
24. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease.
Ripley E
Am Heart J; 2009 Jun; 157(6 Suppl):S7-S16. PubMed ID: 19450722
[TBL] [Abstract][Full Text] [Related]
25. Is angiotensin-II an endogenous pro-inflammatory molecule?
Das UN
Med Sci Monit; 2005 May; 11(5):RA155-162. PubMed ID: 15874906
[TBL] [Abstract][Full Text] [Related]
26. Pharmacotherapy of cognitive deficits in Alzheimer's disease and age-associated memory impairment.
Crook T
Psychopharmacol Bull; 1988; 24(1):31-8. PubMed ID: 3290945
[No Abstract] [Full Text] [Related]
27. Rivastigmine in Parkinson's disease dementia.
Chitnis S; Rao J
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
[TBL] [Abstract][Full Text] [Related]
28. Memory problems in dementia: adaptation and coping strategies and psychosocial treatments.
Dröes RM; van der Roest HG; van Mierlo L; Meiland FJ
Expert Rev Neurother; 2011 Dec; 11(12):1769-81; quiz 1782. PubMed ID: 22091600
[TBL] [Abstract][Full Text] [Related]
29. [Depression and frontal dysfunction: risks for the elderly?].
Thomas P; Hazif Thomas C; Billon R; Peix R; Faugeron P; Clément JP
Encephale; 2009 Sep; 35(4):361-9. PubMed ID: 19748373
[TBL] [Abstract][Full Text] [Related]
30. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition.
Buccafusco JJ; Terry AV
J Pharmacol Exp Ther; 2000 Nov; 295(2):438-46. PubMed ID: 11046074
[TBL] [Abstract][Full Text] [Related]
31. Endothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer's disease?
Isingrini E; Desmidt T; Belzung C; Camus V
Curr Opin Investig Drugs; 2009 Jan; 10(1):46-55. PubMed ID: 19127486
[TBL] [Abstract][Full Text] [Related]
32. Next generation multifunctional angiotensin receptor blockers.
Kurtz TW; Klein U
Hypertens Res; 2009 Oct; 32(10):826-34. PubMed ID: 19713966
[TBL] [Abstract][Full Text] [Related]
33. Cognitive functioning in Alzheimer's and vascular dementia: a meta-analysis.
Mathias JL; Burke J
Neuropsychology; 2009 Jul; 23(4):411-23. PubMed ID: 19586206
[TBL] [Abstract][Full Text] [Related]
34. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.
Männisto PT; Venäläinen J; Jalkanen A; García-Horsman JA
Drug News Perspect; 2007 Jun; 20(5):293-305. PubMed ID: 17878957
[TBL] [Abstract][Full Text] [Related]
35. Androgens and Alzheimer's disease.
Drummond ES; Harvey AR; Martins RN
Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):254-9. PubMed ID: 19373081
[TBL] [Abstract][Full Text] [Related]
36. Impairment of episodic and semantic autobiographical memory in patients with mild cognitive impairment and early Alzheimer's disease.
Leyhe T; Müller S; Milian M; Eschweiler GW; Saur R
Neuropsychologia; 2009 Oct; 47(12):2464-9. PubMed ID: 19409401
[TBL] [Abstract][Full Text] [Related]
37. A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases.
Wright JW; Kawas LH; Harding JW
Front Endocrinol (Lausanne); 2013 Oct; 4():158. PubMed ID: 24298267
[TBL] [Abstract][Full Text] [Related]
38. Subjective memory complaints, education, and risk of Alzheimer's disease.
van Oijen M; de Jong FJ; Hofman A; Koudstaal PJ; Breteler MM
Alzheimers Dement; 2007 Apr; 3(2):92-7. PubMed ID: 19595922
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
40. Prospective and retrospective memory in Alzheimer's disease and vascular dementia: similar patterns of impairment.
Livner A; Laukka EJ; Karlsson S; Bäckman L
J Neurol Sci; 2009 Aug; 283(1-2):235-9. PubMed ID: 19344918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
